{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:41:45Z","timestamp":1779154905463,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Infective endocarditis, typically caused by Gram-positive organisms such as viridans group streptococci and Staphylococcus aureus, is associated with high mortality and morbidity and requires aggressive, prolonged antimicrobial treatment and sometimes surgery. Dalbavancin, a lipoglycopeptide active against Gram-positive pathogens, has a long half-life, which allows IV treatment as one dose or two doses with a prolonged interval, offering personalized treatment for complex psychosocial situations or facilitating early discharge. In the absence of randomized controlled trials in infective endocarditis, current evidence derives from real-world case series involving off-licence use. The Austrian Society for Infectious Disease and Tropical Medicine includes dalbavancin as an option for infective endocarditis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This retrospective case series reports use of dalbavancin in a small cohort of patients with infective endocarditis treated at Lancashire Cardiac Centre, Blackpool Teaching Hospitals Foundation Trust, UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The pharmacy database included 11 patients in whom dalbavancin was used to address either complex psychosocial circumstances or the need for early discharge. The endocarditis multidisciplinary team selected dalbavancin from available treatment options. Structures affected by infective endocarditis included aortic, mitral and tricuspid valves; aortic composite grafts; implantable cardioverter defibrillator leads; and prosthetic aortic valves. Eight patients underwent surgery; three were managed conservatively with antibiotics. Dalbavancin was curative in all but one patient, whose signs and symptoms of infection improved. No patients developed adverse reactions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dalbavancin is an alternative treatment option at hospital discharge when conventional antibiotics may not be suitable due to complex psychosocial issues or early discharge is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlab099","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T11:19:32Z","timestamp":1628507972000},"source":"Crossref","is-referenced-by-count":23,"title":["Use of dalbavancin in infective endocarditis: a case series"],"prefix":"10.1093","volume":"3","author":[{"given":"Achyut","family":"Guleri","sequence":"first","affiliation":[{"name":"Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit","family":"More","sequence":"additional","affiliation":[{"name":"Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Wong","sequence":"additional","affiliation":[{"name":"Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Abdelrahman","sequence":"additional","affiliation":[{"name":"Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2021081217503062300_dlab099-B1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/01.CIR.0000124719.61827.7F","article-title":"Early predictors of in-hospital death in infective endocarditis","volume":"109","author":"Chu","year":"2004","journal-title":"Circulation"},{"key":"2021081217503062300_dlab099-B2","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1001\/jama.293.24.3022","article-title":"Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota","volume":"293","author":"Tleyjeh","year":"2005","journal-title":"JAMA"},{"key":"2021081217503062300_dlab099-B3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/hrt.2003.032128","article-title":"Infective endocarditis in Europe: lessons from the Euro heart survey","volume":"91","author":"Tornos","year":"2005","journal-title":"Heart"},{"key":"2021081217503062300_dlab099-B4","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"2021081217503062300_dlab099-B5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021081217503062300_dlab099-B6","volume-title":"Xydalba 500 mg Powder for Concentrate for Solution for Infusion","author":"Correvio UK Ltd","year":"2019"},{"key":"2021081217503062300_dlab099-B7","volume-title":"Dalvance (Dalbavancin) for Injection, for Intravenous Use","author":"Durata Therapeutics US Ltd","year":"2014"},{"key":"2021081217503062300_dlab099-B8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021081217503062300_dlab099-B9","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2021081217503062300_dlab099-B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021081217503062300_dlab099-B11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081217503062300_dlab099-B12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/44.2.179","article-title":"In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic","volume":"44","author":"Candiani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2021081217503062300_dlab099-B13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijantimicag.2006.05.032","article-title":"Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes","volume":"28","author":"Westling","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2021081217503062300_dlab099-B14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/jac\/dkz006","article-title":"Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres","volume":"74","author":"Sader","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021081217503062300_dlab099-B15","author":"Tobudic","year":"2017"},{"key":"2021081217503062300_dlab099-B16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ejhpharm-2018-001711","article-title":"Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications","volume":"27","author":"N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2021081217503062300_dlab099-B17","volume-title":"Dalbavancin as treatment for endocarditis and\/or bloodstream infections produced by Gram-positive cocci","author":"Tenorio","year":"2018"},{"key":"2021081217503062300_dlab099-B18","author":"Thalhammer","year":"2017"},{"key":"2021081217503062300_dlab099-B19","author":"Thalhammer","year":"2017"},{"key":"2021081217503062300_dlab099-B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/3\/dlab099\/39710953\/dlab099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jacamr\/article-pdf\/3\/3\/dlab099\/39710953\/dlab099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T17:50:55Z","timestamp":1628790655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlab099\/6350002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlab099","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,7,12]]},"article-number":"dlab099"}}